Antibody Discovery and Therapeutics

Mosaic Biosciences works with its partners to advance antibody discovery projects from concept through identification of a preclinical candidate with validated pharmacology and demonstrated drug-like properties.

Antibody Libraries

Mosaic Biosciences' naïve Fab and Nanobody phage display libraries are constructed from synthetic human antibody frameworks and contain natural CDR sequences from hundreds of diverse human donors. We are continuously adding new diversity to our library repertoire; no two libraries are mined for the same target.

Our Fab libraries are built with restricted light chains to enable the discovery of functionally diverse bispecific molecules. Our synthetic Nanobody libraries are engineered using a human developable framework and have been validated to support CAR-T and other targeted delivery applications.

Semi-Synthetic Libraries with 108-9 CDR3 Diversity Amplified from Human Donors
Common Light Chain Fabs and Human VH for Bispecific Engineering
Based on Human Frameworks Selected for Developable Properties
Modular Design Supports Rapid Yeast Display Optimization
Libraries Adapted for Automated Selections and Target Binding Confirmation

Phage Display

The process at Mosaic Biosciences begins with the production and validation of high-quality screening reagents and thoughtful design of a selection strategy aimed at maximizing discovery of diverse and functionally relevant binders. We then apply automation to power parallel selections of our high-diversity human phage display libraries. Discovered antibodies are produced in optimal formats for desired function via our automated high throughput expression platform. We then characterize the antibody panels for affinity, epitope, cell binding, stability, titer, and developability, enabling the rapid curation of lead antibodies for more specialized functional cellular assays.

All Steps
All Steps

Yeast Display

At Mosaic Biosciences, we have designed our phage display libraries to be compatible with our yeast display platform, allowing rapid transition from discovery in phage to lead optimization in yeast. Guided by a Partner’s antibody target profile, we design variant libraries and selection strategies to fine tune lead affinity, specificity, and developability. We produce and characterize a panel of optimized leads for affinity and functional and developability fitness.